Twist Bioscience R&D Spending Growth & History (TWST)
Twist Bioscience's r&d spending was $80.3M for fiscal 2025.
View full Twist Bioscience company overviewTwist Bioscience annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | $80.3M | −$10.6M | −11.63% |
| 2024 | 2024-09-30 | $90.9M | −$16.0M | −15.01% |
| 2023 | 2023-09-30 | $106.9M | −$13.4M | −11.15% |
| 2022 | 2022-09-30 | $120.3M | $51.2M | +74.18% |
| 2021 | 2021-09-30 | $69.1M | $26.1M | +60.61% |
| 2020 | 2020-09-30 | $43.0M | $7.3M | +20.52% |
| 2019 | 2019-09-30 | $35.7M | $15.3M | +75.37% |
| 2018 | 2018-09-30 | $20.3M | $1.2M | +6.15% |
| 2017 | 2017-09-30 | $19.2M | — | — |
Twist Bioscience quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | $18.0M | −$22,000 | −0.12% |
| Q2 2026 | 2026-03-31 | $19.7M | −$4.2M | −17.65% |
| Q1 2026 | 2025-12-31 | $17.1M | −$4.2M | −19.60% |
| Q4 2025 | 2025-09-30 | $17.0M | −$4.1M | −19.50% |
| Q3 2025 | 2025-06-30 | $18.0M | −$4.4M | −19.68% |
| Q2 2025 | 2025-03-31 | $23.9M | −$232,000 | −0.96% |
| Q1 2025 | 2024-12-31 | $21.3M | −$1.8M | −7.76% |
| Q4 2024 | 2024-09-30 | $21.1M | −$2.6M | −10.99% |
| Q3 2024 | 2024-06-30 | $22.5M | −$2.1M | −8.39% |
| Q2 2024 | 2024-03-31 | $24.1M | −$3.2M | −11.80% |
| Q1 2024 | 2023-12-31 | $23.1M | −$8.1M | −26.06% |
| Q4 2023 | 2023-09-30 | $23.7M | −$5.9M | −19.80% |
| Q3 2023 | 2023-06-30 | $24.5M | −$12.3M | −33.42% |
| Q2 2023 | 2023-03-31 | $27.4M | −$3.9M | −12.33% |
| Q1 2023 | 2022-12-31 | $31.2M | $8.6M | +38.06% |
| Q4 2022 | 2022-09-30 | $29.6M | $10.2M | +52.27% |
| Q3 2022 | 2022-06-30 | $36.8M | $17.0M | +85.70% |
| Q2 2022 | 2022-03-31 | $31.2M | $15.4M | +97.78% |
| Q1 2022 | 2021-12-31 | $22.6M | $8.6M | +61.64% |
| Q4 2021 | 2021-09-30 | $19.4M | $7.8M | +67.09% |
| Q3 2021 | 2021-06-30 | $19.8M | $9.4M | +89.95% |
| Q2 2021 | 2021-03-31 | $15.8M | $5.2M | +48.57% |
| Q1 2021 | 2020-12-31 | $14.0M | $3.7M | +35.96% |
| Q4 2020 | 2020-09-30 | $11.6M | $1.1M | +10.86% |
| Q3 2020 | 2020-06-30 | $10.4M | $1.4M | +15.95% |
| Q2 2020 | 2020-03-31 | $10.6M | $1.7M | +19.33% |
| Q1 2020 | 2019-12-31 | $10.3M | $3.0M | +41.58% |
| Q4 2019 | 2019-09-30 | $10.5M | $4.4M | +73.06% |
| Q3 2019 | 2019-06-30 | $9.0M | $3.7M | +70.98% |
| Q2 2019 | 2019-03-31 | $8.9M | $4.2M | +89.07% |
| Q1 2019 | 2018-12-31 | $7.3M | $3.0M | +69.02% |
| Q4 2018 | 2018-09-30 | $6.1M | — | — |
| Q3 2018 | 2018-06-30 | $5.3M | — | — |
| Q2 2018 | 2018-03-31 | $4.7M | — | — |
| Q1 2018 | 2017-12-31 | $4.3M | — | — |
Twist Bioscience r&d spending trends
Over the last five fiscal years, Twist Bioscience's r&d spending increased from $43.0M to $80.3M, a change of $37.3M. The latest reported quarter, Q3 2026, shows $18.0M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Twist Bioscience source filings ↗